Literature DB >> 11840697

Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis.

George Moxley1, Harley J Cohen.   

Abstract

HLA haplotypes influence various clinical RA features considered to reflect severity in case-control and cohort studies. Of particular note is the fact that HLA generally influences the development of erosive and sometimes seropositive and nodular disease; in prospective studies, it noticeably affects joint surgical intervention. These are valuable clues indicating that HLA influences RA severity and chronicity. Nevertheless, HLA influences are generally weak enough so as to require large study subject numbers for detection. As a result, HLA genotyping has restricted usefulness for prediction of clinical severity in individual patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840697     DOI: 10.1016/s0889-857x(03)00068-1

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  7 in total

1.  The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population.

Authors:  H Marotte; B Pallot-Prades; L Grange; J Tebib; P Gaudin; C Alexandre; J L Blond; M A Cazalis; B Mougin; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

2.  Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis.

Authors:  Shunsuke Mori; Jun Hirose; Kensuke Yonemura
Journal:  Clin Rheumatol       Date:  2010-04-11       Impact factor: 2.980

3.  Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene.

Authors:  E Rabinovich; A Livneh; P Langevitz; N Brezniak; E Shinar; M Pras; Y Shinar
Journal:  Ann Rheum Dis       Date:  2005-07       Impact factor: 19.103

4.  Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus.

Authors:  Hye-Soon Lee; Annette T Lee; Lindsey A Criswell; Michael F Seldin; Christopher I Amos; John P Carulli; Cristina Navarrete; Elaine F Remmers; Daniel L Kastner; Robert M Plenge; Wentian Li; Peter K Gregersen
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

5.  Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis.

Authors:  Damini Jawaheer; Wentian Li; Robert R Graham; Wei Chen; Aarti Damle; Xiangli Xiao; Joanita Monteiro; Houman Khalili; Annette Lee; Robert Lundsten; Ann Begovich; Teodorica Bugawan; Henry Erlich; James T Elder; Lindsey A Criswell; Michael F Seldin; Christopher I Amos; Timothy W Behrens; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2002-08-09       Impact factor: 11.025

6.  The contribution of four immunogenetic markers for predicting persistent activity in patients with recent-onset rheumatoid arthritis or undifferentiated arthritis.

Authors:  Sonsoles Reneses; Antonio Fernández-Suárez; Maria F González-Escribano; Luis Pestana; Alicia García
Journal:  ISRN Rheumatol       Date:  2011-08-08

Review 7.  Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Authors:  Vasco Crispim Romão; Helena Canhão; João Eurico Fonseca
Journal:  BMC Med       Date:  2013-01-23       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.